Pasithea Reports Positive Safety Review Committee Recommendation From Phase 1 Study Of PAS-004

(RTTNews) - Pasithea Therapeutics Corp. (KTTA) Thursday said the external Safety Review Committee has recommended that the company's Phase 1 study of PAS-004 in advanced cancer should proceed to cohort 6, next dose level of 30 mg capsule, without modification.

This recommendation was based on the review of the safety data from three patients from Cohort 5 and the absence of any dose limiting toxicities (DLTs). Additionally, no rash, which is a common adverse event, has been observed to date during the DLT period in patients treated with either capsule or tablet formulation of PAS-004.

"We are seeing substantial enrollment demand and have already identified Cohort 6 patients," the company said in a statement.